ANI Pharmaceuticals (ANIP) revenue breakdown
By segment, Rare Disease and Brands is the largest at 55% of fiscal 2025 revenue, growing 81% a year over 3 years.
By product, Generic pharmaceutical products is the largest at 43% of fiscal 2025 revenue; ILUVIEN and YUTIQ grew fastest, 138% a year over 1 years.
Revenue by segment
Fiscal years, as ANI Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $883M.
| Segments | 2018 | 2019 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Rare Disease and Brands | — | — | $81M | $198M | $294M | $484M | 55% |
| Generics and Other | — | — | $235M | $289M | $320M | $399M | 45% |
| United States | $197M | $200M | — | — | — | — | — |
| Canada | $5M | $7M | — | — | — | — | — |
Revenue by product
Fiscal years, as ANI Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $883M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Generic pharmaceutical products | $95M | $118M | $117M | $129M | $147M | $144M | $210M | $269M | $301M | $384M | 43% |
| Cortrophin Gel | — | — | — | — | — | — | $42M | $112M | $198M | $348M | 39% |
| ILUVIEN and YUTIQ | — | — | — | — | — | — | — | — | $32M | $75M | 8% |
| Brands | — | — | — | — | — | — | $39M | $85M | $65M | $61M | 7% |
| Royalties and other pharmaceutical services | — | — | — | — | — | — | $25M | $20M | $19M | $15M | 2% |
| Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services | $26M | $51M | $61M | $64M | $48M | $73M | — | — | — | — | — |
| Sales of contract manufactured products | $6M | $7M | $9M | $11M | $9M | — | — | — | — | — | — |
| Product development services | — | — | $1M | $1M | $2M | — | — | — | — | — | — |
| Royalties from licensing agreements | — | — | $13M | $807,000 | $1M | — | — | — | — | — | — |
| Other | $1M | $440,000 | $929,000 | $980,000 | $783,000 | — | — | — | — | — | — |
Revenue by region
Fiscal years, as ANI Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $883M.
| Regions | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| United States | $197M | $200M | $203M | $212M | $312M | $486M | $605M | $852M | 96% |
| International | $5M | $7M | $6M | $4M | $4M | $565,000 | $9M | $31M | 4% |
Questions
Where does ANI Pharmaceuticals make its money?
In fiscal 2025, by segment: Rare Disease and Brands $484M, Generics and Other $399M.
From ANI Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.